The combination of the enhanced liver fibrosis and FIB-4 scores to determine significant fibrosis in patients with nonalcoholic fatty liver disease.

Autor: Younossi ZM; Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA.; Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia, USA.; Inova Medicine Service Line, Inova Health System, Falls Church, Virginia, USA., Stepanova M; Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA.; Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia, USA.; Inova Medicine Service Line, Inova Health System, Falls Church, Virginia, USA.; Center for Outcomes Research in Liver Diseases, Washington, District of Columbia, USA., Felix S; Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA.; Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia, USA.; Inova Medicine Service Line, Inova Health System, Falls Church, Virginia, USA., Jeffers T; Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA.; Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia, USA.; Inova Medicine Service Line, Inova Health System, Falls Church, Virginia, USA., Younossi E; Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA.; Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia, USA.; Inova Medicine Service Line, Inova Health System, Falls Church, Virginia, USA., Goodman Z; Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA.; Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia, USA.; Inova Medicine Service Line, Inova Health System, Falls Church, Virginia, USA., Racila A; Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA.; Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia, USA.; Inova Medicine Service Line, Inova Health System, Falls Church, Virginia, USA., Lam BP; Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA.; Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia, USA.; Inova Medicine Service Line, Inova Health System, Falls Church, Virginia, USA., Henry L; Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, Virginia, USA.; Center for Liver Disease, Department of Medicine, Inova Fairfax Medical Campus, Falls Church, Virginia, USA.; Inova Medicine Service Line, Inova Health System, Falls Church, Virginia, USA.; Center for Outcomes Research in Liver Diseases, Washington, District of Columbia, USA.
Jazyk: angličtina
Zdroj: Alimentary pharmacology & therapeutics [Aliment Pharmacol Ther] 2023 Jun; Vol. 57 (12), pp. 1417-1422. Date of Electronic Publication: 2023 Mar 26.
DOI: 10.1111/apt.17472
Abstrakt: Background: The presence of fibrosis in NAFLD is the most significant risk factor for adverse outcomes. We determined the cutoff scores of two non-invasive te sts (NITs) to rule in and rule out significant fibrosis among NAFLD patients.
Methods: Clinical data and liver biopsies were used for NAFLD patients included in this analysis (2001-2020). The enhanced liver fibrosis (ELF) and FIB-4 NITs were calculated. Liver biopsies were read by a single hematopathologist and scored by the NASH CRN criteria. Significant fibrosis was defined as stage F2-F4.
Results: There were 463 NAFLD patients included: 48 ± 13 years old, 31% male, 35% type 2 diabetes; 39% had significant fibrosis; mean ELF score was 9.0 ± 1.2, mean FIB-4 score was 1.22 ± 1.05. Patients with significant fibrosis were older, more commonly male, had lower BMI but more components of metabolic syndrome, higher ELF and FIB-4 (p < 0.0001). The performance of the two NITs in identifying significant fibrosis was: AUC (95% CI) = 0.78 (0.74-0.82) for ELF, 0.79 (0.75-0.83) for FIB-4. The combination of ELF score ≥9.8 and FIB-4 ≥ 1.96 returned a positive predictive value of 95% which can reliably rule in significant fibrosis (sensitivity 22%, specificity >99%), while an ELF score ≤7.7 or FIB-4 ≤ 0.30 had a negative predictive value of 95% ruling out significant fibrosis (sensitivity 98%, specificity 22%).
Conclusions: The combination of ELF and FIB-4 may provide practitioners with easily obtained information to risk stratify patients with NAFLD who could be referred to specialists or for enrollment in clinical trials.
(© 2023 John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje